BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 8662951)

  • 61. Purified alpha 2-macroglobulin receptor/LDL receptor-related protein binds urokinase.plasminogen activator inhibitor type-1 complex. Evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes.
    Nykjaer A; Petersen CM; Møller B; Jensen PH; Moestrup SK; Holtet TL; Etzerodt M; Thøgersen HC; Munch M; Andreasen PA
    J Biol Chem; 1992 Jul; 267(21):14543-6. PubMed ID: 1378833
    [TBL] [Abstract][Full Text] [Related]  

  • 62. uPA-silica-Particles (SP-uPA): a novel analytical system to investigate uPA-uPAR interaction and to test synthetic uPAR antagonists as potential cancer therapeutics.
    Guthaus E; Bürgle M; Schmiedeberg N; Hocke S; Eickler A; Kramer MD; Sweep CG; Magdolen V; Kessler H; Schmitt M
    Biol Chem; 2002 Jan; 383(1):207-16. PubMed ID: 11930939
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Vitronectin binding to urokinase receptor in human breast cancer.
    Carriero MV; Del Vecchio S; Franco P; Potena MI; Chiaradonna F; Botti G; Stoppelli MP; Salvatore M
    Clin Cancer Res; 1997 Aug; 3(8):1299-308. PubMed ID: 9815812
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Potential role of kringle-integrin interaction in plasmin and uPA actions (a hypothesis).
    Takada Y
    J Biomed Biotechnol; 2012; 2012():136302. PubMed ID: 23125522
    [TBL] [Abstract][Full Text] [Related]  

  • 65. cDNA transfection of amino-terminal fragment of urokinase efficiently inhibits cancer cell invasion and metastasis.
    Zhu F; Jia S; Xing G; Gao L; Zhang L; He F
    DNA Cell Biol; 2001 May; 20(5):297-305. PubMed ID: 11410166
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Expression of the human urokinase-type plasminogen activator receptor in E. coli and Chinese hamster ovary cells: purification of the recombinant proteins and generation of polyclonal antibodies in chicken.
    Magdolen V; Rettenberger P; Lopens A; Oi H; Lottspeich F; Kellermann J; Creutzburg S; Goretzki L; Weidle UH; Wilhelm O
    Electrophoresis; 1995 May; 16(5):813-6. PubMed ID: 7588568
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Urokinase induces proliferation of human ovarian cancer cells: characterization of structural elements required for growth factor function.
    Fischer K; Lutz V; Wilhelm O; Schmitt M; Graeff H; Heiss P; Nishiguchi T; Harbeck N; Kessler H; Luther T; Magdolen V; Reuning U
    FEBS Lett; 1998 Oct; 438(1-2):101-5. PubMed ID: 9821967
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Urokinase-type plasminogen activator and its receptor synergize to promote pathogenic proteolysis.
    Zhou HM; Nichols A; Meda P; Vassalli JD
    EMBO J; 2000 Sep; 19(17):4817-26. PubMed ID: 10970872
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Requirement of receptor-bound urokinase-type plasminogen activator for integrin alphavbeta5-directed cell migration.
    Yebra M; Parry GC; Strömblad S; Mackman N; Rosenberg S; Mueller BM; Cheresh DA
    J Biol Chem; 1996 Nov; 271(46):29393-9. PubMed ID: 8910604
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator.
    Mahanivong C; Yu J; Huang S
    Mol Carcinog; 2007 Mar; 46(3):165-75. PubMed ID: 17186542
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A cleaved form of the receptor for urokinase-type plasminogen activator in invasive transplanted human and murine tumors.
    Solberg H; Rømer J; Brünner N; Holm A; Sidenius N; Danø K; Høyer-Hansen G
    Int J Cancer; 1994 Sep; 58(6):877-81. PubMed ID: 7927882
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA). Inhibition of proliferation and invasion of human ovarian cancer cells.
    Wilhelm O; Weidle U; Höhl S; Rettenberger P; Schmitt M; Graeff H
    FEBS Lett; 1994 Jan; 337(2):131-4. PubMed ID: 8287966
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Role of urokinase plasminogen activator receptor in thrombospondin 1-mediated tumor cell invasion.
    Albo D; Berger DH; Rothman VL; Tuszynski GP
    J Surg Res; 1999 Apr; 82(2):331-8. PubMed ID: 10090848
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspin.
    Biliran H; Sheng S
    Cancer Res; 2001 Dec; 61(24):8676-82. PubMed ID: 11751384
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The plasminogen activator/plasmin system is up-regulated after acute necrotizing pancreatitis in human beings.
    Friess H; Duarte R; Kleeff J; Fukuda A; Tang WH; Graber H; Schilling M; Zimmermann A; Korc M; Büchler MW
    Surgery; 1998 Jul; 124(1):79-86. PubMed ID: 9663255
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Role of urokinase plasminogen activator and its receptor in metastasis and invasion of neuroblastoma.
    Li P; Gao Y; Ji Z; Zhang X; Xu Q; Li G; Guo Z; Zheng B; Guo X
    J Pediatr Surg; 2004 Oct; 39(10):1512-9. PubMed ID: 15486896
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Single-chain urokinase-type plasminogen activator bound to its receptor is relatively resistant to plasminogen activator inhibitor type 1.
    Higazi AA; Mazar A; Wang J; Reilly R; Henkin J; Kniss D; Cines D
    Blood; 1996 May; 87(9):3545-9. PubMed ID: 8611676
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Inhibition of tumor invasion by genomic down-regulation of matriptase through suppression of activation of receptor-bound pro-urokinase.
    Suzuki M; Kobayashi H; Kanayama N; Saga Y; Suzuki M; Lin CY; Dickson RB; Terao T
    J Biol Chem; 2004 Apr; 279(15):14899-908. PubMed ID: 14747469
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-anilino-1-naphthalenesulfonate. Evidence for a hydrophobic binding site exposed only on the intact receptor.
    Ploug M; Ellis V; Danø K
    Biochemistry; 1994 Aug; 33(30):8991-7. PubMed ID: 8043585
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide.
    Llinas P; Le Du MH; Gårdsvoll H; Danø K; Ploug M; Gilquin B; Stura EA; Ménez A
    EMBO J; 2005 May; 24(9):1655-63. PubMed ID: 15861141
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.